These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 3326651)

  • 21. Podophyllotoxin derivative VP 16-213.
    Arnold AM
    Cancer Chemother Pharmacol; 1979; 3(2):71-80. PubMed ID: 389478
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Treatment of infant leukemia with busulfan, cyclophosphamide +/- etoposide and bone marrow transplantation.
    Emminger W; Emminger-Schmidmeier W; Haas OA; Urban C; Ambros P; Peters C; Mann G; Fink FM; Ferstl G; Höcker P
    Bone Marrow Transplant; 1992 May; 9(5):313-8. PubMed ID: 1617314
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Clinical studies with rubidazone.
    Benjamin RS; Keating MJ; Swenerton KD; Legha S; McCredie KB
    Cancer Treat Rep; 1979 May; 63(5):925-9. PubMed ID: 287557
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [The value of etoposide (VP-16) in the therapy of refractory ovarian cancer].
    Marth C; Pointner E; Zeimet AG; Abfalter E; Koza A; Windbichler G; Hetzel H; Dapunt O
    Geburtshilfe Frauenheilkd; 1993 May; 53(5):303-7. PubMed ID: 8514100
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Treatment of recurrence of acute myeloid leukemia in childhood. A retrospective analysis of recurrence in the AML-BFM-83 study].
    Stahnke K; Ritter J; Schellong G; Beck JD; Kabisch H; Lampert F; Creutzig U
    Klin Padiatr; 1992; 204(4):253-7. PubMed ID: 1518261
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Treatment of 17 cases of non-lymphoblastic acute leukemia with a combination of daunorubicin, cytosine and arabinoside].
    Dini E; Barbui T; Cartei G; Chisesi T; Cazzavillan M; Battista R
    Minerva Med; 1975 Jul; 66(52):2619-2620. PubMed ID: 1057055
    [No Abstract]   [Full Text] [Related]  

  • 27. [Comparison of low-dose cytosine arabinoside and aclarubicin in combination with granulocyte colony-stimulating factor to intermediate-dose cytosine arabinoside and mitoxantrone with or without etoposide in the treatment of relapsed acute myeloid leukemia].
    Saito K; Furusawa S; Yamada K; Waga K; Aoyagi A; Koike T; Arimura H; Noguchi M; Yamato H; Sakuma H
    Rinsho Ketsueki; 1995 Mar; 36(3):165-74. PubMed ID: 7540220
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Congenital monoblastic leukemia and self-healing papulonodular cutaneous lesions].
    Pujol RM; Lopez D; Badell I; Alejo M; Soler J; Aventin A; de Moragas JM
    Ann Dermatol Venereol; 1990; 117(11):878-80. PubMed ID: 2099712
    [No Abstract]   [Full Text] [Related]  

  • 29. Effective remission induction of refractory childhood acute nonlymphocytic leukemia by VP-16-213 plus azacitidine.
    Look AT; Dahl GV; Kalwinsky D; Senzer N; Mason C; Rivera G
    Cancer Treat Rep; 1981; 65(11-12):995-9. PubMed ID: 6170431
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Treatment of acute leukemia in adults.
    Clarkson BD; Dowling MD; Gee TS; Cunningham IB; Burchenal JH
    Cancer; 1975 Aug; 36(2):775-95. PubMed ID: 1057450
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Acute monocytic leukemia in children and its response to vinblastine (NSC-49842).
    Geiser CF; Mitus JW
    Cancer Chemother Rep; 1975; 59(2 Pt 1):385-8. PubMed ID: 1097095
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The distinctive features of acute monocytic leukemia.
    Shaw MT
    Am J Hematol; 1978; 4(1):97-103. PubMed ID: 274906
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Drug-induced kinetic perturbations of the marrow blasts in acute leukemia. Effects of the daunorubicin, cytosine arabinoside and 6-thioguanine combination.
    Amadori S; Petti MC; Mastrovincenzo C; Testa MG
    Acta Haematol; 1979; 61(5):237-42. PubMed ID: 111451
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Aclarubicin in the treatment of elderly patients with acute nonlymphocytic leukemia.
    Takahashi I; Yorimitsu S; Hara M; Inagaki T; Nakada H; Sekito N; Hayashi N; Nonaka K; Ohmoto E; Uchida K
    Acta Med Okayama; 1986 Jun; 40(3):175-7. PubMed ID: 3461685
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Results of treatment with an intensive combination induction regimen containing idarubicin in children with acute myeloblastic leukemia: preliminary report of the Argentine Group for Treatment of Acute Leukemia.
    Sackmann-Muriel F; Fernández-Barbieri MA; Santarelli MT; Matus-Ridley M; Rosso A; Negri-Aranguren P; Cerutti I; Gomel M; Kvicala R
    Semin Oncol; 1993 Dec; 20(6 Suppl 8):34-8. PubMed ID: 8290970
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Phase I study of mitoxantrone plus etoposide with multidrug blockade by SDZ PSC-833 in relapsed or refractory acute myelogenous leukemia.
    Kornblau SM; Estey E; Madden T; Tran HT; Zhao S; Consoli U; Snell V; Sanchez-Williams G; Kantarjian H; Keating M; Newman RA; Andreeff M
    J Clin Oncol; 1997 May; 15(5):1796-802. PubMed ID: 9164187
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Intensive post-remission therapy in acute myeloid leukemia. Results of a prospective comparative study by the South Germany Hemoblastosis Group].
    Hübner G; Link H; Schönrock-Nabulsi P; Wandt H; Gramatzki M; Löffler B; Fackler-Schwalbe I; Queisser W; Brack N; Geer T; Raab M; Ohl S; Schneider B; Schneider C; Freund M; Poliwoda H; Ehninger G
    Med Klin (Munich); 1996 Apr; 91 Suppl 3():26-32. PubMed ID: 8692115
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Effects of FLAG regimen in treatment of refractory or relapsed acute myeloid leukemia].
    Wu XX; Da WM; Li HH; Zhao Y; Wang QS; Wang SH; Zhu HY
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2005 Jun; 13(3):394-6. PubMed ID: 15972128
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Acute monocytic leukemia and acute myelomonocytic leukemia: treatment using VP 16213].
    Amiel JL; Schwarzenberg L; Musset M; De Vassal F; Hayat M; Mathé G
    Bull Cancer; 1974; 61(3):419-26. PubMed ID: 4533742
    [No Abstract]   [Full Text] [Related]  

  • 40. A phase III trial of high-dose cytosine arabinoside with or without etoposide in relapsed and refractory acute myelogenous leukemia. A Southeastern Cancer Study Group trial.
    Vogler WR; McCarley DL; Stagg M; Bartolucci AA; Moore J; Martelo O; Omura GA
    Leukemia; 1994 Nov; 8(11):1847-53. PubMed ID: 7967730
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.